11 hours ago
1
- Liminatus Pharma (NASDAQ:LIMN) added 9% on Tuesday after the company launched a review to consider if it could leverage digital assets in a broader treasury management framework.
- As part of the review, the preclinical-stage cancer drug developer will assess whether novel
English (US) ·